134 related articles for article (PubMed ID: 2702064)
1. Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability.
Lönnerholm G; Kreuger A; Lindström B; Myrdal U
Pediatr Hematol Oncol; 1989; 6(2):105-12. PubMed ID: 2702064
[TBL] [Abstract][Full Text] [Related]
2. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Riccardi R; Balis FM; Ferrara P; Lasorella A; Poplack DG; Mastrangelo R
Pediatr Hematol Oncol; 1986; 3(4):319-24. PubMed ID: 3153245
[TBL] [Abstract][Full Text] [Related]
3. Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children.
Lönnerholm G; Kreuger A; Lindström B; Ludvigsson J; Myrdal U
Pediatr Hematol Oncol; 1986; 3(1):27-35. PubMed ID: 3153216
[TBL] [Abstract][Full Text] [Related]
4. Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia.
Lafolie P; Björk O; Hayder S; Ahström L; Peterson C
Med Oncol Tumor Pharmacother; 1989; 6(4):259-65. PubMed ID: 2615529
[TBL] [Abstract][Full Text] [Related]
5. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.
Kato Y; Matsushita T; Uchida H; Egi S; Yokoyama T; Mohri K
Eur J Clin Pharmacol; 1992; 42(6):619-22. PubMed ID: 1623901
[TBL] [Abstract][Full Text] [Related]
6. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.
Lafolie P; Hayder S; Björk O; Peterson C
Eur J Clin Pharmacol; 1991; 40(6):599-601. PubMed ID: 1884741
[TBL] [Abstract][Full Text] [Related]
7. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Zuccaro P; Guandalini S; Pacifici R; Pichini S; Di Martino L; Guiducci M; Giuliano M; Di Tullio MT; Pettoello Mantovani M
Ther Drug Monit; 1991 Jan; 13(1):37-41. PubMed ID: 2057989
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia.
Kato Y; Matsushita T; Chiba K; Hijiya N; Yokoyama T; Ishizaki T
J Pediatr; 1991 Aug; 119(2):311-6. PubMed ID: 1861221
[TBL] [Abstract][Full Text] [Related]
9. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.
Welch J; Lennard L; Morton GC; Lilleyman JS
Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia.
Jacqz-Aigrain E; Nafa S; Médard Y; Bessa E; Lescoeur B; Vilmer E
Eur J Clin Pharmacol; 1997; 53(1):71-4. PubMed ID: 9349933
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Ogungbenro K; Aarons L;
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
[TBL] [Abstract][Full Text] [Related]
14. Importance of oral antimetabolite "maintenance" therapy in childhood lymphoblastic leukemia.
Lilleyman JS
Pediatr Hematol Oncol; 1996; 13(5):vii-x. PubMed ID: 10897808
[No Abstract] [Full Text] [Related]
15. The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia.
Hayder S; Björk O; Lafolie P
Acta Paediatr Scand; 1990; 79(8-9):832-7. PubMed ID: 2239280
[TBL] [Abstract][Full Text] [Related]
16. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM
Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780
[TBL] [Abstract][Full Text] [Related]
17. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
[TBL] [Abstract][Full Text] [Related]
18. The effect of food on the oral administration of 6-mercaptopurine.
Burton NK; Barnett MJ; Aherne GW; Evans J; Douglas I; Lister TA
Cancer Chemother Pharmacol; 1986; 18(1):90-1. PubMed ID: 3757164
[TBL] [Abstract][Full Text] [Related]
19. Detection and identification of 6-methylmercapto-8-hydoxypurine, a major metabolite of 6-mercaptopurine, in plasma during intravenous administration.
Keuzenkamp-Jansen CW; van Baal JM; De Abreu RA; de Jong JG; Zuiderent R; Trijbels JM
Clin Chem; 1996 Mar; 42(3):380-6. PubMed ID: 8598099
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children.
Mawatari H; Unei K; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2001 Dec; 43(6):673-7. PubMed ID: 11737747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
